NEW YORK (GenomeWeb News) – Bruker reported today that its revenues in the third quarter were down 2 percent year over year, falling to $439 million from $447.8 million in Q3 2012.

The drop was driven by weakness in the company's Energy and Semiconducting Technologies (BEST) segment, which saw revenue decline by 27 percent in the quarter. Bruker's Scientific Instruments segment, which includes its mass spectrometry and life sciences business, grew a fraction of 1 percent year over year.

The results fell short of the average Wall Street estimate of $452.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.